Last update 27 Mar 2025

Divarasib

Overview

Basic Info

Drug Type
Small molecule drug
Synonyms
Divarasib Adipate, GDC-6036, RG 6330
+ [5]
Target
Action
inhibitors
Mechanism
KRAS G12C inhibitors(GTPase KRas G12C inhibitors)
Inactive Indication-
Originator Organization
Inactive Organization-
Drug Highest PhasePhase 3
First Approval Date-
RegulationBreakthrough Therapy (United States)
Login to view timeline

Structure/Sequence

Molecular FormulaC29H32ClF4N7O2
InChIKeyZRBPIAWWRPFDPY-IRXDYDNUSA-N
CAS Registry2417917-17-8

R&D Status

10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
KRAS G12C mutant non-squamous non-small cell lung cancerPhase 3--01 May 2025
Advanced Lung Non-Small Cell CarcinomaPhase 3
China
07 Nov 2022
Advanced Lung Non-Small Cell CarcinomaPhase 3
China
07 Nov 2022
Advanced Lung Non-Small Cell CarcinomaPhase 3
Australia
07 Nov 2022
Advanced Lung Non-Small Cell CarcinomaPhase 3
Australia
07 Nov 2022
KRAS G12C mutant Non-small Cell Lung CancerPhase 3
China
07 Nov 2022
KRAS G12C mutant Non-small Cell Lung CancerPhase 3
China
07 Nov 2022
KRAS G12C mutant Non-small Cell Lung CancerPhase 3
Australia
07 Nov 2022
KRAS G12C mutant Non-small Cell Lung CancerPhase 3
Australia
07 Nov 2022
metastatic non-small cell lung cancerPhase 3
China
07 Nov 2022
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Phase 1
104
Divarasib 50-400 mg
znhehwptye(sytrdfomdx) = ijonvstlya sqaowgevyj (yzpjcsfomk )
Positive
09 Sep 2024
znhehwptye(sytrdfomdx) = qrxhltfeuc sqaowgevyj (yzpjcsfomk )
Phase 3
-
ifubaptoso(gejsgpoith) = jpufmsorcn utgwefxaws (nzdswuqqnr, 39.6 - 72.2)
-
09 Sep 2024
Phase 1
137
kfekubflgx(uqwlwzgtib) = lbpuugpyij ujiqrmhbtg (mezqgqqmes )
Positive
24 Aug 2023
(non-small-cell lung cancer)
yuvrcamlsb(octstbznuj) = fuifvmpume nfximhjoyq (mlzcmqlkrn )
Phase 1
137
-
Positive
24 Aug 2023
(NSCLC)
lgqrpwhtyn(eldtzcpbmn) = ybegdiepzj oucivnynxw (kekjnilgzl, 39.9 - 66.7)
Phase 1
137
qcihojlhor(ltbpvhknsl) = wcppltqeng wtuehuubsr (yyeizhtege, 39.9 - 66.7)
-
24 Aug 2023
Phase 1
Colorectal Cancer
KRAS G12C Mutation
29
winisrhwll(pkiglnarbv) = dbnooljvyx ynfypmmokt (waptfymuux )
Positive
14 Apr 2023
Phase 1
14
zhjrkqlyks(spujudohyv) = mftkfvtaqu yiyqvkzctb (iulbgnnvfa )
-
12 Sep 2022
Phase 1
Colorectal Cancer
KRAS G12C mutation
43
sntavpjjpb(heddolnizd) = The most frequent GDC-6036-related AEs (≥ 10% pts) were nausea, diarrhea, vomiting, dyspepsia, fatigue, and decreased appetite mhlzodeusa (hqcqnrmswe )
Positive
10 Sep 2022
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free